(GMAB) Genmab AS - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 16.471m USD | Total Return: 51.2% in 12m
Antibody Therapies, Cancer Drugs, Blood Disorders, Autoimmune Disease
Total Rating 57
Safety 64
Buy Signal 0.41
Biotechnology
Industry Rotation: +3.6
Industry Rotation: +3.6
Market Cap:
16.5B
Avg Turnover: 33.9M USD
Avg Turnover: 33.9M USD
ATR:
2.80%
Peers RS (IBD): 24.3
Peers RS (IBD): 24.3
Risk 5d forecast
Volatility33.5%
Rel. Tail Risk0.28%
Reward TTM
Sharpe Ratio1.15
Alpha34.99
Character TTM
Beta0.581
Beta Downside0.871
Drawdowns 3y
Max DD58.13%
CAGR/Max DD-0.19
EPS (Earnings per Share)
EPS CAGR: -50.63%
EPS Trend: 6.4%
EPS Trend: 6.4%
Last SUE: -0.65
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 36.05%
Rev. Trend: -11.9%
Rev. Trend: -11.9%
Last SUE: 0.00
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: GMAB Genmab AS
Genmab A/S is a biotechnology company focused on developing antibody-based treatments for cancer and other diseases. The company markets several approved drugs, including EPKINLY, TEPKINLY, and Tivdak, targeting various cancers such as diffuse large B-cell lymphoma and cervical cancer. The biotechnology sector is characterized by high research and development costs and a long drug development timeline.
Genmabs product pipeline includes numerous drug candidates in various stages of development for conditions like solid tumors, non-small cell lung cancer, and ovarian cancer. The company utilizes a business model common in biotech, involving extensive collaboration agreements with larger pharmaceutical companies like Johnson & Johnson and Pfizer Inc. for drug development and commercialization.
For more detailed financial and operational data, consider exploring ValueRays comprehensive analysis.
- EPKINLY and TEPKINLY sales growth drives revenue
- DARZALEX royalty revenue remains a key income source
- Clinical trial success or failure impacts future drug pipeline
- Regulatory approvals for new indications expand market access
- Collaboration agreements with pharma partners provide funding
Piotroski VR‑10 (Strict)
5.0
| Net Income: 2.92b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.50 > 1.0 |
| NWC/Revenue: 64.74% < 20% (prev 168.7%; Δ -104.0% < -1%) |
| CFO/TA 0.06 > 3% & CFO 4.79b > Net Income 2.92b |
| Net Debt (24.45b) to EBITDA (5.15b): 4.75 < 3 |
| Current Ratio: 2.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (672.6m) vs 12m ago 4.84% < -2% |
| Gross Margin: 93.19% > 18% (prev 0.95%; Δ 9.22k% > 0.5%) |
| Asset Turnover: 22.44% > 50% (prev 29.17%; Δ -6.73% > 0%) |
| Interest Coverage Ratio: 10.07 > 6 (EBITDA TTM 5.15b / Interest Expense TTM 344.6m) |
Altman Z''
2.73
| A: 0.11 (Total Current Assets 18.35b - Total Current Liabilities 9.07b) / Total Assets 81.86b |
| B: 0.32 (Retained Earnings 26.06b / Total Assets 81.86b) |
| C: 0.05 (EBIT TTM 3.47b / Avg Total Assets 63.83b) |
| D: 0.56 (Book Value of Equity 24.97b / Total Liabilities 44.68b) |
| Altman-Z'' Score: 2.73 = A |
Beneish M
-2.28
| DSRI: 1.02 (Receivables 7.33b/6.69b, Revenue 14.32b/13.36b) |
| GMI: 1.02 (GM 93.19% / 95.02%) |
| AQI: 2.15 (AQ_t 0.75 / AQ_t-1 0.35) |
| SGI: 1.07 (Revenue 14.32b / 13.36b) |
| TATA: -0.02 (NI 2.92b - CFO 4.79b) / TA 81.86b) |
| Beneish M-Score: -2.28 (Cap -4..+1) = BBB |
What is the price of GMAB shares?
As of April 06, 2026, the stock is trading at USD 27.50 with a total of 1,081,600 shares traded.
Over the past week, the price has changed by +6.47%, over one month by +0.07%, over three months by -13.52% and over the past year by +51.18%.
Over the past week, the price has changed by +6.47%, over one month by +0.07%, over three months by -13.52% and over the past year by +51.18%.
Is GMAB a buy, sell or hold?
Genmab AS has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy GMAB.
- StrongBuy: 4
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GMAB price?
| Wallstreet Target Price | 37.1 | 35.1% |
| Analysts Target Price | 37.1 | 35.1% |
GMAB Fundamental Data Overview
as of 02 April 2026
P/E Trailing = 18.1284 P/E Forward = 14.556
P/S = 4.4277
P/B = 3.729
P/EG = 1.0776
Revenue TTM = 14.32b USD
EBIT TTM = 3.47b USD
EBITDA TTM = 5.15b USD
Long Term Debt = 5.00b USD (from longTermDebt, last quarter)
Short Term Debt = 1.85b USD (from shortTermDebt, last quarter)
Debt = 35.36b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 24.45b USD (from netDebt column, last quarter)
Enterprise Value = 40.92b USD (16.47b + Debt 35.36b - CCE 10.91b)
Interest Coverage Ratio = 10.07 (Ebit TTM 3.47b / Interest Expense TTM 344.6m)
EV/FCF = 9.21x (Enterprise Value 40.92b / FCF TTM 4.44b)
FCF Yield = 10.85% (FCF TTM 4.44b / Enterprise Value 40.92b)
FCF Margin = 31.01% (FCF TTM 4.44b / Revenue TTM 14.32b)
Net Margin = 20.40% (Net Income TTM 2.92b / Revenue TTM 14.32b)
Gross Margin = 93.19% ((Revenue TTM 14.32b - Cost of Revenue TTM 975.9m) / Revenue TTM)
Gross Margin QoQ = 92.34% (prev 94.32%)
Tobins Q-Ratio = 0.50 (Enterprise Value 40.92b / Total Assets 81.86b)
Interest Expense / Debt = 0.79% (Interest Expense 279.6m / Debt 35.36b)
Taxrate = 43.64% (152.5m / 349.5m)
NOPAT = 1.96b (EBIT 3.47b * (1 - 43.64%))
Current Ratio = 2.02 (Total Current Assets 18.35b / Total Current Liabilities 9.07b)
Debt / Equity = 0.95 (Debt 35.36b / totalStockholderEquity, last quarter 37.18b)
Debt / EBITDA = 4.75 (Net Debt 24.45b / EBITDA 5.15b)
Debt / FCF = 5.51 (Net Debt 24.45b / FCF TTM 4.44b)
Total Stockholder Equity = 27.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.58% (Net Income 2.92b / Total Assets 81.86b)
RoE = 10.61% (Net Income TTM 2.92b / Total Stockholder Equity 27.53b)
RoCE = 10.67% (EBIT 3.47b / Capital Employed (Equity 27.53b + L.T.Debt 5.00b))
RoIC = 28.49% (NOPAT 1.96b / Invested Capital 6.87b)
WACC = 2.86% (E(16.47b)/V(51.83b) * Re(8.03%) + D(35.36b)/V(51.83b) * Rd(0.79%) * (1-Tc(0.44)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.11%
[DCF] Terminal Value 86.90% ; FCFF base≈3.75b ; Y1≈3.98b ; Y5≈4.74b
[DCF] Fair Price = 188.3 (EV 140.06b - Net Debt 24.45b = Equity 115.61b / Shares 613.9m; r=6.0% [WACC]; 5y FCF grow 6.66% → 3.0% )
EPS Correlation: 6.41 | EPS CAGR: -50.63% | SUE: -0.65 | # QB: 0
Revenue Correlation: -11.89 | Revenue CAGR: 36.05% | SUE: -0.00 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.28 | Chg7d=-0.052 | Chg30d=-0.052 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-12-31): EPS=1.09 | Chg7d=+0.072 | Chg30d=-0.134 | Revisions Net=+1 | Growth EPS=-38.3% | Growth Revenue=+16.6%
EPS next Year (2027-12-31): EPS=1.79 | Chg7d=-0.023 | Chg30d=-0.123 | Revisions Net=+0 | Growth EPS=+63.4% | Growth Revenue=+18.5%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.5% (Discount Rate 8.0% - Earnings Yield 5.5%)
[Growth] Growth Spread = +13.0% (Analyst 15.5% - Implied 2.5%)
External Resources